Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about unit size escalation, not just volume growth. Look for comparisons against own past, real and recurring, early stage. Scan transcript for mentions of deals, orders, contracts, projects, customers, sites, programs. Management talks about growth, new customers, coverage expansion, salesforce expansion, Stelo launch, etc. But does it say that each new instance is larger? For example, "we added over 600,000 users" - that's volume. "We expanded prescriber base by 40%" - that's more prescribers, not necessarily larger deals. "More than 70% of new scripts from PCPs" - that's mix. Look for any statement about average size of orders, contracts, or deals increasing. Not present. Management discusses G7 launch, basal coverage, Stelo. No mention of larger contracts or projects. The only thing about "larger" might be the expansion of coverage population, but that's not about unit size of engagements. It's about market size. Also, management talks about investing in salesforce to expand coverage, but that's about more reps, not larger deals. No mention of deals, orders, contracts, projects, customers, sites, or programs being individually larger. So answer NO. Check if any analyst question hints at it, but management doesn't affirm. For example, question about basal contribution, but that's about volume. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.